Improved Prediction of Prostate Cancer Recurrence through Systems Pathology
Complete the form below to unlock access to ALL audio articles.
Aureon Laboratories and their collaborators announced the publication of their 'Systems Pathology' model for predicting prostate cancer PSA recurrence in the Journal of Clinical Investigation (JCI).
The article supports the Prostate Px® prognostic test which provides patients and their physicians a personalized determination of their risk for prostate cancer recurrence following removal of the prostate.
The JCI article, now available online and in print describes Aureon's integrated Systems Pathology approach to generate accurate predictive tools for complex diseases such as prostate cancer.
The article reviews data obtained in a cohort of 850 men with prostate cancer. Aureon scientists used machine learning tools to develop a model based on clinicopathological variables, histologic tumor characteristics, and cell-type specific protein biomarker quantitation.
The study, utilizing both immunohistochemistry and quantitative immunofluorescence, determined that high levels of androgen receptor were associated with a reduced time to PSA recurrence. Aureon's System Pathology approach is the foundation of Prostate Px.
"We are very excited that a high-impact medical journal such as the Journal of Clinical Investigation has decided to publish data generated by Aureon's System Pathology approach. We believe that peer-reviewed publications support the validity of Aureon's technology and approach. Critically important, this technology is available to patients and physicians as Prostate Px which significantly enhances the decision making process," stated Vijay Aggarwal, Ph.D., Aureon's CEO and President.
Prostate Px can provide physicians with a unique insight into a patient's chance of developing a cancer recurrence following the removal of the prostate. The physician receives a Px SCORE® for both the probability of PSA recurrence (bio-chemical recurrence) and disease progression (distant metastasis).